Clinical Summary
Clinical Summary: Randomized Controlled Trial of Mindfulness Meditation for Generalized Anxiety Disorder: Effects on Anxiety and Stress Reactivity
Many patients with generalized anxiety disorder remain symptomatic despite standard treatment, and some avoid specialty psychiatric care altogether. This trial tests whether a structured mindfulness program offers benefit beyond a time- and attention-matched stress education intervention, with outcomes that matter clinically: anxiety, sleep, and response to acute stress.
Design
the first randomized, controlled trial (RCT) of mindfulness meditation without added cognitive therapy, compared to an active control condition
N
Ninety-three individuals with DSM-IV-diagnosed GAD
Population
Individuals 18 years or older were eligible if they (1) met DSM-IV criteria for current primary GAD and designated GAD as the primary problem and (2) scored 20 or above on the Hamilton Anxiety Rating Scale (HAMA).
Duration
an 8-week group intervention with MBSR or to an attention control, Stress Management Education (SME)
Key Findings
- Responder status was greater for MBSR than SME: 29/44; 66% versus 14/35; 40% (P = .025), with a risk ratio of 1.65 (95% CI, 1.04-2.60) and number needed to treat of 3.9 (95% CI, 2.23-26.19).
- On the primary HAMA outcome, both groups had significant improvement from baseline to endpoint (P < .0001), but the treatment arm ×— time interaction was not significant (F1,87 = 1.38, P = .244).
- MBSR produced greater improvement in self-reported anxiety than SME on the BAI, with a significant treatment arm ×— time interaction (F1,79 = 4.31, P = .041).
- Stress reactivity improved more with MBSR on the TSST: STAI-S scores dropped from 53.9 to 40.8 versus 52.2 to 45.2 with SME, with a significant treatment arm ×— time interaction (F1,73 = 4.37, P = .040); SUDS scores dropped from 53.2 to 28.7 versus 50.5 to 39.4, with a significant treatment arm ×— time interaction (F1,68 = 5.25, P = .025).
- Among participants not taking psychiatric medications (n = 61), sleep improved more with MBSR than SME: mean change score [SD] for PSQI for MBSR = 2.6 [3.6], SME = 1.0 [1.9], with a significant treatment arm ×— time interaction (F1,59 = 4.69, P = .035); positive self-statements during the TSST also increased more with MBSR (15.9 to 18.6) than SME (16.9 to 16.5) (F1,72 = 8.64, P = .004).
Clinical Bottom Line
For patients with GAD, Mindfulness-Based Stress Reduction improved global anxiety outcomes, response rates, and stress-task coping more than an active stress education control, even though the primary HAMA outcome did not separate between groups. MBSR is a credible nonpharmacologic treatment option to add when worry, stress reactivity, or insomnia remain prominent.
Practice Implications
- Consider MBSR as an evidence-based group option for GAD when patients want a nonpharmacologic treatment or have persistent symptoms despite usual care; the response rate was 66% with MBSR versus 40% with SME.
- Do not rely on a single somatically weighted anxiety scale to judge benefit; in this trial, HAMA did not differ between groups, while CGI-S, CGI-I, and BAI favored MBSR.
- When insomnia is part of the presentation, note that sleep improved more with MBSR among participants not taking psychiatric medications (PSQI mean change score [SD] for MBSR = 2.6 [3.6], SME = 1.0 [1.9]).
- Discuss mindfulness training not only as symptom management but as a way to improve coping under stress, given larger reductions in TSST anxiety and distress and increased positive self-statements with MBSR.
